Evidence map›Paper›PMID 36675126›Full record

ArticleInternational journal of molecular sciences2023

ProNGF Expression and Targeting in Glioblastoma Multiforme.

Mark Marsland, Amiee Dowdell, Sam Faulkner, Phillip Jobling, Robert A Rush, Craig Gedye, James Lynam, Cassandra P Griffin, Mark Baker, Joanne Marsland and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Nerve growth factor receptor (NGFR): A key player in glioblastoma progression.Biochimica et biophysica acta. Reviews on cancer · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Journal of Cancer · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Mark MarslandSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW 2308, Australia.
Amiee DowdellSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW 2308, Australia.
Sam FaulknerSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW 2308, Australia.ORCID 0000-0002-4732-8252
Phillip JoblingSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW 2308, Australia.
Robert A RushBiosensis Pty Ltd., Thebarton, SA 5031, Australia.
Craig GedyeHunter Medical Research Institute, University of Newcastle, New Lambton Heights, NSW 2305, Australia.
James LynamHunter Medical Research Institute, University of Newcastle, New Lambton Heights, NSW 2305, Australia.ORCID 0000-0002-6742-820X
Cassandra P GriffinSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW 2308, Australia.ORCID 0000-0003-4107-0921
Mark BakerSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW 2308, Australia.
Joanne MarslandSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW 2308, Australia.
Chen Chen JiangSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW 2308, Australia.
Hubert HondermarckSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW 2308, Australia.ORCID 0000-0003-3807-2985
Hunter Medical Research Institute · AU

Funding

Mark Hughes Foundation (MHF), New South Wales, Australia G1900631
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is the most lethal adult brain cancer. Temozolomide (TMZ), the standard chemotherapeutic drug used in GBM, has limited benefit and alternate therapies are needed to improve GBM treatment. Nerve growth factor (NGF) and its precursor proNGF are increasingly recognized as stimulators of human tumor progression. The expression and stimulatory effect of NGF on GBM cell growth has previously been reported, but the status of proNGF in GBM is unreported. In this study, we have investigated proNGF expression and biological activity in GBM. A clinical cohort of GBM (

Indexed as

Antineoplastic Agents, AlkylatingBrain NeoplasmsGlioblastomaGliomaTemozolomideCell Line, TumorDNA Modification MethylasesDNA Repair EnzymesDrug Resistance, NeoplasmHumansNerve Growth FactorTumor Suppressor ProteinsAntineoplastic Agents, AlkylatingDNA Modification MethylasesDNA Repair EnzymesMGMT protein, humanNerve Growth FactorNGF protein, humanTemozolomideTumor Suppressor Proteinsbiomarkerglioblastoma multiformeproNGFtherapeutic target

Identifiers

PMID36675126
PMCPMC9863529
OpenAlexW4315864874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.